ストックスクリーナーアプリを入手
27.07
2.65%
0.70
前日終値:
$26.37
開ける：
$25.86
24時間の取引高:
1.92M
Relative Volume:
0.50
時価総額：
$20.10B
収益：
$956.00K
当期純損益:
$-221.32M
株価収益率:
-84.59
EPS:
-0.32
ネットキャッシュフロー:
$-142.25M
1週間 パフォーマンス:
-5.58%
1か月 パフォーマンス:
+27.69%
6か月 パフォーマンス:
+25.91%
1年 パフォーマンス:
+153.94%
1日の値動き範囲:
$25.41
$27.44
1週間の範囲:
$25.41
$28.71
52週間の値動き範囲:
$8.88
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
SMMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
27.07 | 19.58B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-01 | 開始されました | UBS | Buy |
| 2025-06-11 | 開始されました | Leerink Partners | Underperform |
| 2025-03-26 | アップグレード | Citigroup | Neutral → Buy |
| 2025-03-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 開始されました | Evercore ISI | Outperform |
| 2025-02-28 | 開始されました | Goldman | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-11-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-07 | 開始されました | Citigroup | Buy |
| 2024-03-26 | 開始されました | Stifel | Buy |
| 2018-06-28 | ダウングレード | Janney | Buy → Neutral |
| 2018-05-02 | 開始されました | Janney | Buy |
| 2018-04-12 | 繰り返されました | Needham | Buy |
| 2018-02-13 | 開始されました | BTIG Research | Buy |
| 2018-01-04 | 開始されました | SunTrust | Buy |
| 2017-12-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-05 | 繰り返されました | Needham | Buy |
| 2016-09-16 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-30 | 開始されました | Needham | Buy |
| 2015-03-30 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Summit Therapeutics Inc (SMMT) 最新ニュース
Strategies to average down on Summit Therapeutics Inc.Trend Confirmation Scanner with Entry Focus - Newser
Using data tools to time your Summit Therapeutics Inc. exitShort Squeeze Opportunities with Indicators - Newser
Can Summit Therapeutics Inc. rally from current levelsAI Screener for Daily Stock Forecast - Newser
Commit To Buy Summit Therapeutics At $18, Earn 30.8% Annualized Using Options - Nasdaq
What’s the recovery path for long term holders of Summit Therapeutics Inc.Free Buy Signal Based on Chart Analysis - Newser
How high can Summit Therapeutics Inc. stock goProfit Target Planning with Exit Confidence - Newser
Advanced analytics toolkit walkthrough for Tyra Biosciences Inc.Free Low Drawdown Real Time Trading Tips - Newser
Summit Therapeutics Inc. recovery potential after sell offConsistent Return Setup with Exit Strategy - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Is Summit Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSmart Trade Mapping with Entry Details - Newser
Is Summit Therapeutics Inc. stock a growth or value playFree Day Trading Signals With High Precision - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire
Summit Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Is Summit Therapeutics Inc. stock poised for growthTechnical Setup Guide for Daily Watchlist - Newser
Why is Summit Therapeutics Inc. stock attracting strong analyst attentionRapid-fire capital growth - jammulinksnews.com
Summit Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Ivonescimab's Dual-Action Revolution: A Catalyst for Akeso and Summit Therapeutics in the $500M+ Lung Cancer Market - AInvest
What are the technical indicators suggesting about Summit Therapeutics Inc.Invest confidently with data-driven strategies - jammulinksnews.com
Does Summit Therapeutics Inc. stock perform well during market downturnsBuild a portfolio that withstands market volatility - jammulinksnews.com
Summit Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowFree Stock Market Courses - Newser
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - ETX View
Is Summit Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisVolume Spike Monitors - Newser
When is Summit Therapeutics Inc. stock expected to show significant growthAchieve consistent profits with proven strategies - jammulinksnews.com
Summit Therapeutics Jumps 4% As Technicals Signal Bullish Breakout Potential - AInvest
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Summit Therapeutics Soars 4.64%—Could This Biotech Breakthrough Signal a Game-Changer? - AInvest
What analysts say about Summit Therapeutics Inc. stockSky-high profits - PrintWeekIndia
What drives Summit Therapeutics Inc. stock priceConsistent double returns - Autocar Professional
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bank of New York Mellon Corp Has $6.57 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World
Will Summit Therapeutics Inc. stock benefit from AI tech trendsTriple-digit growth rates - jammulinksnews.com
Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings - MSN
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Is Summit Therapeutics Inc. a good long term investmentHigh-octane financial growth - Autocar Professional
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Meet the Biotech Stock That Rocketed 775% Higher - AOL.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Investors to Connect - ACCESS Newswire
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - The Motley Fool
Summit Therapeutics Inc. Stock Analysis and ForecastDouble-digit growth - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich - Yahoo Finance
3 Monster Stocks in the Making to Buy Right Now - The Globe and Mail
Trading (SMMT) With Integrated Risk Controls - news.stocktradersdaily.com
Summit Therapeutics PLC (NASDAQ:SMMT) Shares Acquired by Cerity Partners LLC - Defense World
Summit Therapeutics Inc (SMMT) 財務データ
収益
当期純利益
現金流量
EPS
1.31%
0.15%
大文字化:
|
ボリューム (24 時間):